

Lipum welcomes Dr. Peter Hovstadius as Chief Medical Officer

Lipum AB (publ) recruits Peter Hovstadius as the new Chief Medical Officer (CMO). Peter Hovstadius is a specialist in clinical pharmacology with a PhD in drug development from Uppsala University.

Peter Hovstadius has a long career in both the pharmaceutical industry and academia. He has previously been in leading positions such as Chief Medical Officer at XNK Therapeutics, Chief Scientific Officer at Novartis and Research Director at MSD. Peter has through these roles, gained extensive experience in clinical drug development, and he has also been a driving force behind several important research and development initiatives in the pharmaceutical sector.

"I am very happy to become part of Lipum and working to improve treatment options for patients with chronic inflammatory diseases. It feels very inspiring to use my experience and expertise in a company that is so dedicated to making a difference for patients. I am really looking forward to working with the team at Lipum and contributing to our shared vision " says Peter Hovstadius.

Peter replaces Karin Franck-Larsson who has chosen to leave Lipum at her own request.

"I have had the privilege of working with Karin at both Lipum and Sobi. She has been a very appreciated colleague who has contributed greatly to Lipum with her expertise in rheumatology and drug development, and I would like to extend my genuine thank you to her. Peter has valuable and extensive experience in the role of CMO as well as pharmacology and clinical trials. His strong drive and commitment will contribute to the success of our continued clinical development. Peter will be an important member of our team, and I am pleased to welcome him to Lipum", says CEO Ola Sandborgh

Contacts

Ola Sandborgh, CEO

ola.sandborgh@lipum.se

+46 72 218 80 21

Web: www.lipum.se

About Us

Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

PRESS RELEASE

19 August 2024 08:30:00 CEST



Attachments

[Lipum welcomes Dr. Peter Hovstadius as Chief Medical Officer](#)